ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,606.99
0.31%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Palatin Technologies Inc New (PTN)

  7. Palatin Technologies Inc New (PTN) Noticias

PTN Palatin Technologies Inc New

1.827
0.107 (6.22%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Palatin Technologies Inc New PTN AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.107 6.22% 1.827 17:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.72 1.68 1.83 1.82 1.72
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202406:30PRNUSPalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease..
07/3/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202411:57EDGAR2Form 144 - Report of proposed sale of securities
28/2/202406:30PRNUSPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3..
15/2/202408:00EDGAR2Form 8-K - Current report
15/2/202406:30PRNUSPalatin Reports Second Quarter Fiscal Year 2024 Financial..
14/2/202415:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/2/202413:55EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202406:30PRNUSPalatin to Report Second Quarter Fiscal Year 2024 Results;..
05/2/202406:30PRNUSPalatin Announces Database Lock for PL9643 MELODY-1 Pivotal..
01/2/202416:16EDGAR2Form 8-K - Current report
01/2/202415:00PRNUSPalatin Announces Closing of $10 Million Registered Direct..
30/1/202407:00PRNUSPalatin Announces $10 Million Registered Direct Offering
08/1/202409:33PRNUSPalatin Provides Corporate Update and Highlights Strategic..
03/1/202407:00BWCosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide..
20/12/202308:00EDGAR2Form 8-K - Current report
20/12/202306:30PRNUSPalatin Completes Sale of Vyleesi® to Cosette..
18/12/202315:45EDGAR2Form 8-K - Current report
18/12/202315:15PRNUSPalatin Receives Notice of Acceptance of the Listing..
17/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
08/12/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202316:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202313:25EDGAR2Form 144 - Report of proposed sale of securities
04/12/202316:00EDGAR2Form S-1 - General form for registration of securities under..
01/12/202314:52EDGAR2Form 144 - Report of proposed sale of securities
14/11/202306:30PRNUSPalatin Reports First Quarter Fiscal Year 2024 Financial..
09/11/202306:30PRNUSPalatin to Report First Quarter Fiscal Year 2024 Results;..
24/10/202315:50PRNUSPalatin Announces Closing of $5 Million Registered Direct..
24/10/202315:05EDGAR2Form 8-K - Current report
23/10/202306:30PRNUSPalatin Announces $5 Million Registered Direct Offering
19/10/202307:01EDGAR2Form 8-K - Current report
19/10/202306:30PRNUSPalatin Announces Preliminary Quarter Ended September 30,..
18/10/202306:30PRNUSPalatin Announces Positive Preclinical Data Showing..
16/10/202306:30PRNUSPalatin Presents Data at the United European..
13/10/202315:31EDGAR2Form 8-K - Current report
13/10/202315:15PRNUSPalatin Receives Notice of Non-Compliance from NYSE American
28/9/202307:02EDGAR2Form 8-K - Current report
28/9/202307:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/9/202306:30PRNUSPalatin Reports Fourth Quarter and Fiscal Year Ended 2023..
22/9/202315:00PRNUSPalatin to Report Fourth Quarter and Fiscal Year End 2023..
08/9/202307:00EDGAR2Form 8-K - Current report
07/9/202315:00PRNUSPalatin to Present at the H.C. Wainwright 25th Annual Global..
07/9/202307:49EDGAR2Form 8-K - Current report
07/9/202306:30PRNUSPalatin Completes Enrollment in Phase 3 MELODY-1 Study of..
16/8/202320:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202320:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202307:15EDGAR2Form 8-K - Current report
10/8/202306:30PRNUSPalatin Initiates Clinical Program for Bremelanotide..
08/8/202307:00EDGAR2Form 8-K - Current report
08/8/202306:30PRNUSPalatin's Vyleesi® Licensee Fosun Pharma Reports First..

Su Consulta Reciente

AMEX
PTN
Palatin Technologies
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados